Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer

CONCLUSION: A majority of patients with mCRPC never receive BTAs prior to first SRE, despite universal access and availability of these agents in Ontario. These results highlight an opportunity to improve outcomes by emphasizing early introduction of BTA in patients with mCRPC being started on systemic therapy.PMID:38527096 | DOI:10.1093/oncolo/oyae036

Source: The Oncologist - March 25, 2024 Category: Cancer & Oncology Authors: William J Phillips Fred Saad Jennifer Leigh Alborz Jooya Colleen Webber Scott Morgan Robert MacRae Jean-Marc Bourque Peter Tanuseputro Michael Ong Source Type: research